# Supplementary Material

## Supplementary Tables

Table S1. Differences by type of advanced therapy (gene therapies versus cell and tissue therapies)

| Design and methodology of the pivotal trial | Gene Therapies | Non-Gene Therapies |
|---------------------------------------------|----------------|--------------------|
| Mean (SD) number of pivotal clinical trials | 1.27 (0.65)    | 1.14 (0.38)        |
| Phase of the trials                         |                |                    |
| Phase 1, Phase 1/2, Phase 2 and retrospective trials | 7 | 3 |
| Phase 2/3 and Phase 3 | 7 | 6 |
| Type of control                             |                |                    |
| Non-controlled\(^2\)                         | 13             | 3                  |
| Placebo or active controlled                | 1              | 6                  |
| Randomisation                               |                |                    |
| Yes                                         | 2              | 6                  |
| No                                          | 12             | 3                  |
| Blinding design                             |                |                    |
| Open                                        | 14             | 7                  |
| Single or double                            | 0              | 2                  |
| Blinding evaluation                         |                |                    |
| Yes                                         | 2              | 7                  |
| No                                          | 12             | 2                  |
| Multicentre                                 |                |                    |
| Yes                                         | 11             | 9                  |
| No                                          | 3              | 0                  |
| Number of arms                              |                |                    |
| 1 arm                                       | 11             | 2                  |
| ≥ 2 arms                                    | 3              | 7                  |
| Design                                      |                |                    |
| Parallel                                    | 2              | 6                  |
| Other\(^1\)                                 | 12             | 3                  |
| Type of objective                           |                |                    |
| Superiority and non-inferiority             | 1              | 6                  |
| Other                                       | 13             | 3                  |
| Main outcome                                |                |                    |
| Final variable                              | 2              | 3                  |
| Intermediate variable                       | 12             | 6                  |
| Type of primary variable                    |                |                    |
| Number of quantitative variables            | 13             | 4                  |
| Number of qualitative variables             | 2              | 5                  |
| Health-related quality of life variables    |                |                    |
| Yes                                         | 9              | 7                  |
| No                                          | 7              | 3                  |

Sample size (n=17): Gene therapies (n= 10), non-gene therapies (n=7). Non-gene therapies comprise both cell and tissue engineered medicinal products. \(^1\) Including 1 retrospective study; \(^2\) Including historical controls and ‘other’ studies; \(^3\) Including single, crossover and “other” studies. SD: standard deviation.